Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy

Anticancer vaccination is a promising approach to increase the efficacy of cytotoxic T lymphocyte–associated protein 4 (CTLA-4) and programmed death ligand 1 (PD-L1) checkpoint blockade therapies. However, the landmark FDA registration trial for anti–CTLA-4 therapy (ipilimumab) revealed a complete l...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Invest
Main Authors: Hailemichael, Yared, Woods, Amber, Fu, Tihui, He, Qiuming, Nielsen, Michael C., Hasan, Farah, Roszik, Jason, Xiao, Zhilan, Vianden, Christina, Khong, Hiep, Singh, Manisha, Sharma, Meenu, Faak, Faisal, Moore, Derek, Dai, Zhimin, Anthony, Scott M., Schluns, Kimberly S., Sharma, Padmanee, Engelhard, Victor H., Overwijk, Willem W.
Format: Artigo
Sprog:Inglês
Udgivet: American Society for Clinical Investigation 2018
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5873868/
https://ncbi.nlm.nih.gov/pubmed/29480817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI93303
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker